Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. Among authors: taurelli salimbeni b. JAMA Oncol. 2024 May 1;10(5):658-670. doi: 10.1001/jamaoncol.2023.7322. JAMA Oncol. 2024. PMID: 38512229 Review.
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, Sajjadi E, Zagami P, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Corti C, De Camilli E, Curigliano G, Fusco N, Criscitiello C. Morganti S, et al. Among authors: taurelli salimbeni b. Eur J Cancer. 2023 Dec;195:113397. doi: 10.1016/j.ejca.2023.113397. Epub 2023 Oct 23. Eur J Cancer. 2023. PMID: 37890353
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, Malapelle U. Venetis K, et al. Among authors: taurelli salimbeni b. Cancer Treat Rev. 2023 Dec;121:102642. doi: 10.1016/j.ctrv.2023.102642. Epub 2023 Oct 13. Cancer Treat Rev. 2023. PMID: 37864956 Review.
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, Pescia C, Fusco N, Curigliano G, Criscitiello C. Antonarelli G, et al. Among authors: taurelli salimbeni b. Crit Rev Oncol Hematol. 2023 Dec;192:104148. doi: 10.1016/j.critrevonc.2023.104148. Epub 2023 Oct 1. Crit Rev Oncol Hematol. 2023. PMID: 37783318 Review.
12 results